No Data
No Data
Hoyuan Biotech (688238.SH): Shareholders Shanghai Tan Ying, Shanghai Qiangang, and Shanghai Leyong have collectively reduced their shareholding by 0.9990% in the company.
On September 9th, Gelonghui announced that Hemay Bio (688238.SH) has recently received a notice from shareholders Shanghai Tianying, Shanghai Qiangang, and Shanghai Leyong regarding the expiration of the shareholding reduction plan and equity changes reaching 1%. As of September 6th, 2024, shareholders Shanghai Tianying, Shanghai Qiangang, and Shanghai Leyong have cumulatively reduced the company's shareholding through centralized bidding trading by 6,467,856 shares, holding a total of 45,871,444 shares. The shareholding reduction plan of shareholders Shanghai Tianying, Shanghai Qiangang, and Shanghai Leyong has reached the end of the designated time range, and this shareholding reduction plan has been fully implemented.
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
HiFiBio (688238.SH) released its semi-annual performance results with a net loss of 113 million yuan.
Huayuan Biology (688238.SH) disclosed its semi-annual report for 2024, and the company achieved revenue of 1.13 million during the reporting period...
Hua Yuan Bio (688238.SH): net loss of 0.113 billion yuan in the first half of the year.
Gelonghui released its semi-annual report on August 28. During the reporting period, the company achieved operating revenue of 113.0616 million yuan, a year-on-year increase of 35.00%. The net income attributable to the owners of the parent company was -113.3454 million yuan, and the net income attributable to the owners of the parent company after deducting non-recurring gains and losses was -119.4092 million yuan, a decrease compared to the same period last year. The net cash flow from operating activities was -114.6298 million yuan, a decrease compared to the same period last year. This is mainly due to the continuous impact of the external investment and financing environment, as well as the domestic cell and foundation.
OBiO Technology Congratulates on The First Clinical Gene Editing Therapy to Treat An Overseas Patient in China by CorrectSequence Therapeutics
No Data
No Data